KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $11,156 | -8.9% | 1,785 | -11.1% | 0.00% | 0.0% |
| Q4 2022 | $12,249 | -44.7% | 2,008 | +8.4% | 0.00% | 0.0% |
| Q3 2022 | $22,131 | -5.2% | 1,852 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $23,354 | +12.0% | 1,852 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $20,854 | -84.3% | 1,852 | -75.3% | 0.00% | -50.0% |
| Q4 2021 | $133,077 | -23.0% | 7,510 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $172,880 | +18.2% | 7,510 | +60.0% | 0.00% | +50.0% |
| Q1 2021 | $146,234 | – | 4,693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |